Beckman Coulter-BARDA Partnership Expanded for Sepsis Diagnostic and Prediction Algorithm in COVID-19 Patients
By HospiMedica International staff writers Posted on 18 May 2020 |
Illustration
Beckman Coulter (Brea, CA, USA) has been awarded an expanded partnership with BARDA as part of their rapidly expanding COVID-19 medical countermeasure portfolio.
The partnership was awarded to Beckman Coulter, in collaboration with Dascena, Inc. (Oakland, CA, USA) for additional advanced research and development toward optimization of a machine-learning based sepsis diagnostic and prediction algorithm to include assessing its use with coronavirus (COVID-19) patients.
The sepsis diagnostic and prediction algorithm builds on Beckman Coulter's existing Early Sepsis Indicator, which received FDA 510(k) clearance in April 2019, combining the monocyte distribution width (MDW) novel laboratory test parameter values with Dascena's electronic health record data based machine-learning algorithm to help accurately predict and detect those with sepsis.
"Until recently, the majority of sepsis cases have been thought to be caused by bacterial pathogens," said Shamiram R. Feinglass, M.D., MPH, chief medical officer, Beckman Coulter. "COVID-19 is changing that, and causing a paradigm shift in how we think about sepsis. The aim of the study is to determine whether MDW, as part of the sepsis prediction algorithm, will be able to aid in the detection of sepsis regardless of whether it is bacterial or viral-induced."
The COVID-19 specific study is part of BARDA's Rapidly Deployable Capabilities program to identify and pilot near-term innovative solutions for COVID-19, leveraging the development of Beckman Coulter's digital sepsis prediction algorithm under BARDA's Division of Research Innovation and Venture's (DRIVe's) Solving Sepsis Program.
"The global impact that COVID-19 has had on the health system is undeniable. It has changed the way the industry thinks about so many things, and sepsis is no exception," said Peter Soltani, Ph.D., senior vice president and general manager of the hematology business unit at Beckman Coulter. "Beckman Coulter is deeply committed to the fight against COVID-19 and has been working diligently to quickly bring quality SARS-CoV-2 serology assays to the market. We are thrilled to expand our partnership with BARDA, so we can extend that commitment to our sepsis research and begin clinical trials that include COVID-19 patients."
The partnership was awarded to Beckman Coulter, in collaboration with Dascena, Inc. (Oakland, CA, USA) for additional advanced research and development toward optimization of a machine-learning based sepsis diagnostic and prediction algorithm to include assessing its use with coronavirus (COVID-19) patients.
The sepsis diagnostic and prediction algorithm builds on Beckman Coulter's existing Early Sepsis Indicator, which received FDA 510(k) clearance in April 2019, combining the monocyte distribution width (MDW) novel laboratory test parameter values with Dascena's electronic health record data based machine-learning algorithm to help accurately predict and detect those with sepsis.
"Until recently, the majority of sepsis cases have been thought to be caused by bacterial pathogens," said Shamiram R. Feinglass, M.D., MPH, chief medical officer, Beckman Coulter. "COVID-19 is changing that, and causing a paradigm shift in how we think about sepsis. The aim of the study is to determine whether MDW, as part of the sepsis prediction algorithm, will be able to aid in the detection of sepsis regardless of whether it is bacterial or viral-induced."
The COVID-19 specific study is part of BARDA's Rapidly Deployable Capabilities program to identify and pilot near-term innovative solutions for COVID-19, leveraging the development of Beckman Coulter's digital sepsis prediction algorithm under BARDA's Division of Research Innovation and Venture's (DRIVe's) Solving Sepsis Program.
"The global impact that COVID-19 has had on the health system is undeniable. It has changed the way the industry thinks about so many things, and sepsis is no exception," said Peter Soltani, Ph.D., senior vice president and general manager of the hematology business unit at Beckman Coulter. "Beckman Coulter is deeply committed to the fight against COVID-19 and has been working diligently to quickly bring quality SARS-CoV-2 serology assays to the market. We are thrilled to expand our partnership with BARDA, so we can extend that commitment to our sepsis research and begin clinical trials that include COVID-19 patients."
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans